Total Payments
$3,666
2024 Payments
$147.37
Companies
20
Transactions
211
Medicare Patients
2,749
Medicare Billing
$783,540
Payment Breakdown by Category
Food & Beverage$3,431 (93.6%)
Education$234.89 (6.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,431 | 206 | 93.6% |
| Education | $234.89 | 5 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| OPKO Pharmaceuticals, LLC | $897.61 | 52 | $0 (2024) |
| Relypsa, Inc. | $411.93 | 30 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $395.00 | 16 | $0 (2020) |
| Mallinckrodt Enterprises LLC | $377.54 | 18 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $362.39 | 23 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $217.78 | 16 | $0 (2024) |
| Horizon Therapeutics plc | $212.63 | 13 | $0 (2021) |
| Keryx Biopharmaceuticals, Inc. | $205.70 | 16 | $0 (2018) |
| Amgen Inc. | $140.47 | 6 | $0 (2021) |
| GlaxoSmithKline, LLC. | $114.34 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $147.37 | 8 | GlaxoSmithKline, LLC. ($58.96) |
| 2023 | $195.57 | 11 | AstraZeneca Pharmaceuticals LP ($73.12) |
| 2022 | $80.29 | 4 | Mallinckrodt Hospital Products Inc. ($37.94) |
| 2021 | $612.02 | 35 | OPKO Pharmaceuticals, LLC ($239.26) |
| 2020 | $331.16 | 21 | OPKO Pharmaceuticals, LLC ($152.83) |
| 2019 | $1,213 | 72 | OPKO Pharmaceuticals, LLC ($290.40) |
| 2018 | $847.25 | 47 | Mallinckrodt LLC ($216.29) |
| 2017 | $239.25 | 13 | Relypsa, Inc. ($105.25) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 4 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/30/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/22/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/16/2020 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: KRYSTEXXA | ||||||
| 01/07/2020 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Hyperparathyroidism | ||||||
| 12/20/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: Hyperkalemia | ||||||
| 12/18/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.69 | General |
| Category: NEPHROLOGY | ||||||
| 12/12/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 12/12/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $2.69 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 12/05/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Hyperkalemia | ||||||
| 12/04/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Hyperparathyroidism | ||||||
| 12/03/2019 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: NEPHROLOGY | ||||||
| 11/21/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.51 | General |
| Category: NEPHROLOGY | ||||||
| 11/06/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Hyperparathyroidism | ||||||
| 11/06/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $6.84 | General |
| Category: Hyperkalemia | ||||||
| 10/23/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: Nephrology | ||||||
| 10/23/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $7.50 | General |
| Category: NEPHROLOGY | ||||||
| 10/22/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $3.43 | General |
| Category: Hyperparathyroidism | ||||||
| 10/17/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $7.77 | General |
| Category: KRYSTEXXA | ||||||
| 10/10/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: KRYSTEXXA | ||||||
| 10/08/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $3.63 | General |
| Category: Hyperkalemia | ||||||
| 10/03/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: Hyperparathyroidism | ||||||
| 09/26/2019 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Education | In-kind items and services | $61.20 | General |
| Category: NEPHROLOGY | ||||||
| 09/25/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.78 | General |
| Category: NEPHROLOGY | ||||||
| 09/25/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: Hyperkalemia | ||||||
| 09/18/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $38.90 | General |
| Category: Hyperparathyroidism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 624 | 1,499 | $481,409 | $144,322 |
| 2022 | 13 | 692 | 1,835 | $562,881 | $176,777 |
| 2021 | 10 | 706 | 2,042 | $758,710 | $261,356 |
| 2020 | 12 | 727 | 1,977 | $631,091 | $201,085 |
Total Patients
2,749
Total Services
7,353
Medicare Billing
$783,540
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 32 | 206 | $187,954 | $57,811 | 30.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 228 | 793 | $162,130 | $50,075 | 30.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 94 | 106 | $35,767 | $10,394 | 29.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 86 | $26,418 | $8,079 | 30.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 55 | $24,607 | $7,105 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 64 | $21,486 | $5,442 | 25.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 42 | 53 | $9,765 | $3,063 | 31.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 27 | 31 | $7,328 | $1,017 | 13.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 13 | $3,088 | $818.51 | 26.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 12 | 23 | $322.00 | $175.03 | 54.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 11 | 20 | $1,140 | $101.60 | 8.9% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 11 | 16 | $720.00 | $90.56 | 12.6% |
| 84550 | Uric acid level, blood | Office | 2023 | 12 | 18 | $324.00 | $79.74 | 24.6% |
| 84100 | Phosphate level | Office | 2023 | 12 | 15 | $360.00 | $69.75 | 19.4% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 47 | 214 | $194,526 | $62,885 | 32.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 262 | 1,051 | $188,129 | $60,316 | 32.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 27 | 63 | $47,502 | $15,506 | 32.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 115 | 119 | $40,460 | $12,305 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 49 | 111 | $28,638 | $9,094 | 31.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 37 | $18,426 | $5,973 | 32.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 52 | 92 | $21,436 | $4,287 | 20.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 40 | 50 | $9,200 | $3,021 | 32.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 23 | $7,567 | $1,890 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 14 | $4,606 | $1,191 | 25.9% |
| 82043 | Urine microalbumin (protein) level | Office | 2022 | 11 | 19 | $855.00 | $108.38 | 12.7% |
About Dr. James Tomas, MD
Dr. James Tomas, MD is a Nephrology healthcare provider based in San Bernardino, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/22/2009. The National Provider Identifier (NPI) number assigned to this provider is 1902040819.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Tomas, MD has received a total of $3,666 in payments from pharmaceutical and medical device companies, with $147.37 received in 2024. These payments were reported across 211 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($3,431).
As a Medicare-enrolled provider, Tomas has provided services to 2,749 Medicare beneficiaries, totaling 7,353 services with total Medicare billing of $783,540. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location San Bernardino, CA
- Active Since 04/22/2009
- Last Updated 06/24/2014
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1902040819
Products in Payments
- RAYALDEE (Drug) $452.58
- Rayaldee (Drug) $445.03
- Veltassa (Drug) $437.56
- ACTHAR (Biological) $415.48
- Auryxia (Drug) $262.67
- JYNARQUE (Drug) $214.58
- KRYSTEXXA (Biological) $212.63
- FARXIGA (Drug) $185.08
- SAMSCA (Drug) $180.42
- LOKELMA (Drug) $177.31
- AURYXIA (Drug) $160.81
- BENLYSTA (Biological) $114.34
- Parsabiv (Biological) $71.67
- Parsabiv (Drug) $68.80
- INJECTAFER (Drug) $57.02
- Kerendia (Drug) $43.69
- TARPEYO (Drug) $43.33
- ELIQUIS (Drug) $41.91
- Velphoro (Drug) $35.43
- ELELYSO (Drug) $24.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in San Bernardino
Dr. Sreesh Iyengar, Md, MD
Nephrology — Payments: $119,021
Nephrology $119,021
Parag Mehtani, M.d, M.D
Nephrology — Payments: $30,766
Nephrology $30,766
Dr. Ashok Nath, M.d.,, M.D.,
Nephrology — Payments: $12,861
Nephrology $12,861
Dr. Daniel Hwang, M.d, M.D
Nephrology — Payments: $6,617
Nephrology $6,617
Jay Agarwal, M.d, M.D
Nephrology — Payments: $3,618
Nephrology $3,618
Sapna Singh, Md, MD
Nephrology — Payments: $373.09
Nephrology $373.09